Antibody data
- Antibody Data
- Antigen structure
- References [63]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Immunohistochemistry [2]
- Other assay [5]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-12759 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ErbB2 (HER-2) Monoclonal Antibody (9G6.10)
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- MA5-12759 targets HER-2 in FACS, IF, IHC (F), and IP applications and shows reactivity with Human samples.
- Antibody clone number
- 9G6.10
- Concentration
- 0.2 mg/mL
Submitted references Multiplexed Molecular Imaging of Biomarker-Targeted SERS Nanoparticles on Fresh Tissue Specimens with Channel-Compressed Spectrometry.
Quantitative molecular phenotyping with topically applied SERS nanoparticles for intraoperative guidance of breast cancer lumpectomy.
Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device.
Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential.
Oxidatively modified proteins as plasma biomarkers in breast cancer.
Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers.
T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment.
Circulating Tumor Cells Detected by RT-PCR for CK-20 before Surgery Indicate Worse Prognostic Impact in Triple-Negative and HER2 Subtype Breast Cancer.
Multiplexed cancer biomarker detection using quartz-based photonic crystal surfaces.
Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody.
Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma.
Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept.
Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes.
Clinical outcomes and breast cancer subtypes in patients with brain metastases.
Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.
Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling.
Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation.
Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery.
Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule.
Caspase cleavage of HER-2 releases a Bad-like cell death effector.
Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification.
Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism.
Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.
Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment.
Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, erbB2.
Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu.
Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics.
A large-scale proteomic analysis of human embryonic stem cells.
Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.
Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.
Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK.
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.
Effect of vitamin D analog (1alpha hydroxy D5) immunoconjugated to Her-2 antibody on breast cancer.
Changes in the expression and cytological localization of betacellulin and its receptors (ErbB-1 and ErbB-4) in the trophoblasts in human placenta over the course of pregnancy.
Changes in the expression and cytological localization of betacellulin and its receptors (ErbB-1 and ErbB-4) in the trophoblasts in human placenta over the course of pregnancy.
Transmembrane peptides as inhibitors of ErbB receptor signaling.
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells.
Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.
Effects of cytochalasin D on the actin cytoskeleton: association of neoformed actin aggregates with proteins involved in signaling and endocytosis.
Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells.
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway.
Basolateral targeting of ERBB2 is dependent on a novel bipartite juxtamembrane sorting signal but independent of the C-terminal ERBIN-binding domain.
Basolateral targeting of ERBB2 is dependent on a novel bipartite juxtamembrane sorting signal but independent of the C-terminal ERBIN-binding domain.
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.
Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain.
Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA.
ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation.
Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.
Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol.
Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol.
Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.
ErbB-4 ribozymes abolish neuregulin-induced mitogenesis.
Kang S, Wang Y, Reder NP, Liu JT
PloS one 2016;11(9):e0163473
PloS one 2016;11(9):e0163473
Quantitative molecular phenotyping with topically applied SERS nanoparticles for intraoperative guidance of breast cancer lumpectomy.
Wang Y, Kang S, Khan A, Ruttner G, Leigh SY, Murray M, Abeytunge S, Peterson G, Rajadhyaksha M, Dintzis S, Javid S, Liu JT
Scientific reports 2016 Feb 16;6:21242
Scientific reports 2016 Feb 16;6:21242
Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device.
Galletti G, Sung MS, Vahdat LT, Shah MA, Santana SM, Altavilla G, Kirby BJ, Giannakakou P
Lab on a chip 2014 Jan 7;14(1):147-56
Lab on a chip 2014 Jan 7;14(1):147-56
Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential.
Mosoyan G, Nagi C, Marukian S, Teixeira A, Simonian A, Resnick-Silverman L, DiFeo A, Johnston D, Reynolds SR, Roses DF, Mosoian A
PloS one 2013;8(1):e55145
PloS one 2013;8(1):e55145
Oxidatively modified proteins as plasma biomarkers in breast cancer.
Jin H, Daly DS, Marks JR, Zangar RC
Cancer biomarkers : section A of Disease markers 2013;13(3):193-200
Cancer biomarkers : section A of Disease markers 2013;13(3):193-200
Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
Gunaherath GM, Marron MT, Wijeratne EM, Whitesell L, Gunatilaka AA
Bioorganic & medicinal chemistry 2013 Sep 1;21(17):5118-29
Bioorganic & medicinal chemistry 2013 Sep 1;21(17):5118-29
Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers.
Hernandez LI, Flenker KS, Hernandez FJ, Klingelhutz AJ, McNamara JO 2nd, Giangrande PH
Pharmaceuticals (Basel, Switzerland) 2013 Mar 14;6(3):295-319
Pharmaceuticals (Basel, Switzerland) 2013 Mar 14;6(3):295-319
T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment.
Miller KR, Koide A, Leung B, Fitzsimmons J, Yoder B, Yuan H, Jay M, Sidhu SS, Koide S, Collins EJ
PloS one 2012;7(8):e43746
PloS one 2012;7(8):e43746
Circulating Tumor Cells Detected by RT-PCR for CK-20 before Surgery Indicate Worse Prognostic Impact in Triple-Negative and HER2 Subtype Breast Cancer.
Hwang SB, Bae JW, Lee HY, Kim HY
Journal of breast cancer 2012 Mar;15(1):34-42
Journal of breast cancer 2012 Mar;15(1):34-42
Multiplexed cancer biomarker detection using quartz-based photonic crystal surfaces.
Huang CS, Chaudhery V, Pokhriyal A, George S, Polans J, Lu M, Tan R, Zangar RC, Cunningham BT
Analytical chemistry 2012 Jan 17;84(2):1126-33
Analytical chemistry 2012 Jan 17;84(2):1126-33
Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody.
Wu X, Subramaniam M, Negron V, Cicek M, Reynolds C, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC, Hawse JR
Journal of cellular biochemistry 2012 Feb;113(2):711-23
Journal of cellular biochemistry 2012 Feb;113(2):711-23
Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma.
Menju T, Hashimoto S, Hashimoto A, Otsuka Y, Handa H, Ogawa E, Toda Y, Wada H, Date H, Sabe H
PloS one 2011;6(9):e25301
PloS one 2011;6(9):e25301
Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept.
Eifler RL, Lind J, Falkenhagen D, Weber V, Fischer MB, Zeillinger R
Cytometry. Part B, Clinical cytometry 2011 Mar;80(2):100-11
Cytometry. Part B, Clinical cytometry 2011 Mar;80(2):100-11
Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes.
Lee YR, Huh SJ, Lee DH, Yoon HH, Seol YM, Choi YJ, Kwon KA, Lee S, Oh SY, Kim SH, Kim HJ, Kwon HC
Journal of breast cancer 2011 Jun;14(2):140-6
Journal of breast cancer 2011 Jun;14(2):140-6
Clinical outcomes and breast cancer subtypes in patients with brain metastases.
Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, Choi YJ, Cho GJ, Kim YS, Lee M, Lee JH, Kim DC, Lee HS, Cho SH, Kim HJ
Onkologie 2010;33(4):146-52
Onkologie 2010;33(4):146-52
Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.
Mahajan K, Challa S, Coppola D, Lawrence H, Luo Y, Gevariya H, Zhu W, Chen YA, Lawrence NJ, Mahajan NP
The Prostate 2010 Sep 1;70(12):1274-85
The Prostate 2010 Sep 1;70(12):1274-85
Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling.
Pfister AB, Wood RC, Salas PJ, Zea DL, Ramsauer VP
Journal of cellular biochemistry 2010 Oct 15;111(3):643-52
Journal of cellular biochemistry 2010 Oct 15;111(3):643-52
Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation.
Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C, Muraoka-Cook RS, Cheng JQ, Schönbrunn E, Sebti SM, Earp HS, Mahajan NP
PloS one 2010 Mar 19;5(3):e9646
PloS one 2010 Mar 19;5(3):e9646
Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
Kimple RJ, Vaseva AV, Cox AD, Baerman KM, Calvo BF, Tepper JE, Shields JM, Sartor CI
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Feb 1;16(3):912-23
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Feb 1;16(3):912-23
Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery.
Milano F, Guarriera M, Rygiel AM, Krishnadath KK
PloS one 2010 Aug 26;5(8):e12424
PloS one 2010 Aug 26;5(8):e12424
Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
van der Groep P, van Diest PJ, Menko FH, Bart J, de Vries EG, van der Wall E
Journal of clinical pathology 2009 Oct;62(10):926-30
Journal of clinical pathology 2009 Oct;62(10):926-30
Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule.
Vernet E, Konrad A, Lundberg E, Nygren PA, Gräslund T
Journal of immunological methods 2008 Sep 30;338(1-2):1-6
Journal of immunological methods 2008 Sep 30;338(1-2):1-6
Caspase cleavage of HER-2 releases a Bad-like cell death effector.
Strohecker AM, Yehiely F, Chen F, Cryns VL
The Journal of biological chemistry 2008 Jun 27;283(26):18269-82
The Journal of biological chemistry 2008 Jun 27;283(26):18269-82
Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification.
Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL, El-Naggar AK
Human pathology 2008 Jan;39(1):15-20
Human pathology 2008 Jan;39(1):15-20
Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism.
Fan YX, Wong L, Ding J, Spiridonov NA, Johnson RC, Johnson GR
The Journal of biological chemistry 2008 Jan 18;283(3):1588-96
The Journal of biological chemistry 2008 Jan 18;283(3):1588-96
Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.
Katsumi Y, Kuwahara Y, Tamura S, Kikuchi K, Otabe O, Tsuchiya K, Iehara T, Kuroda H, Hosoi H, Sugimoto T
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Feb 15;14(4):1192-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Feb 15;14(4):1192-9
Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment.
Milano F, Jorritsma T, Rygiel AM, Bergman JJ, Sondermeijer C, Ten Brinke A, vanHam SM, Krishnadath KK
Scandinavian journal of immunology 2008 Dec;68(6):616-23
Scandinavian journal of immunology 2008 Dec;68(6):616-23
Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, erbB2.
Xu Y, Darcy PK, Kershaw MH
Cancer gene therapy 2007 Sep;14(9):773-80
Cancer gene therapy 2007 Sep;14(9):773-80
Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu.
Garrett JT, Rawale S, Allen SD, Phillips G, Forni G, Morris JC, Kaumaya PT
Journal of immunology (Baltimore, Md. : 1950) 2007 Jun 1;178(11):7120-31
Journal of immunology (Baltimore, Md. : 1950) 2007 Jun 1;178(11):7120-31
Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics.
Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, Ma W, Hoa N, Minev B, Delgado C, Wepsic HT, Okada H, Jadus MR
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Jan 15;13(2 Pt 1):566-575
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Jan 15;13(2 Pt 1):566-575
A large-scale proteomic analysis of human embryonic stem cells.
Schulz TC, Swistowska AM, Liu Y, Swistowski A, Palmarini G, Brimble SN, Sherrer E, Robins AJ, Rao MS, Zeng X
BMC genomics 2007 Dec 27;8:478
BMC genomics 2007 Dec 27;8:478
Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.
Muraoka-Cook RS, Caskey LS, Sandahl MA, Hunter DM, Husted C, Strunk KE, Sartor CI, Rearick WA Jr, McCall W, Sgagias MK, Cowan KH, Earp HS 3rd
Molecular and cellular biology 2006 Sep;26(17):6412-24
Molecular and cellular biology 2006 Sep;26(17):6412-24
Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT, Metz MZ, Kane SE
Breast cancer research and treatment 2005 May;91(2):187-201
Breast cancer research and treatment 2005 May;91(2):187-201
Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.
Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, French FS, Wilson EM, Earp HS 3rd
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Mar 1;11(5):1704-12
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Mar 1;11(5):1704-12
Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.
Dakappagari NK, Lute KD, Rawale S, Steele JT, Allen SD, Phillips G, Reilly RT, Kaumaya PT
The Journal of biological chemistry 2005 Jan 7;280(1):54-63
The Journal of biological chemistry 2005 Jan 7;280(1):54-63
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW, Earp HS, Whang YE
Cancer research 2005 Apr 15;65(8):3404-9
Cancer research 2005 Apr 15;65(8):3404-9
Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK.
Kansra S, Stoll SW, Johnson JL, Elder JT
Molecular biology of the cell 2004 Sep;15(9):4299-309
Molecular biology of the cell 2004 Sep;15(9):4299-309
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB
Molecular cancer research : MCR 2004 Nov;2(11):606-19
Molecular cancer research : MCR 2004 Nov;2(11):606-19
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.
Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ, Gradishar WJ, Nicholson BP, Merkel DE, Murrey D, Edgerton S, Sledge GW Jr
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Mar 15;22(6):1071-7
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Mar 15;22(6):1071-7
Effect of vitamin D analog (1alpha hydroxy D5) immunoconjugated to Her-2 antibody on breast cancer.
Punj V, Graves JM, Mehta RR
International journal of cancer 2004 Mar 1;108(6):922-9
International journal of cancer 2004 Mar 1;108(6):922-9
Changes in the expression and cytological localization of betacellulin and its receptors (ErbB-1 and ErbB-4) in the trophoblasts in human placenta over the course of pregnancy.
Tanimura K, Nakago S, Murakoshi H, Takekida S, Moriyama T, Matsuo H, Hashimoto K, Maruo T
European journal of endocrinology 2004 Jul;151(1):93-101
European journal of endocrinology 2004 Jul;151(1):93-101
Changes in the expression and cytological localization of betacellulin and its receptors (ErbB-1 and ErbB-4) in the trophoblasts in human placenta over the course of pregnancy.
Tanimura K, Nakago S, Murakoshi H, Takekida S, Moriyama T, Matsuo H, Hashimoto K, Maruo T
European journal of endocrinology 2004 Jul;151(1):93-101
European journal of endocrinology 2004 Jul;151(1):93-101
Transmembrane peptides as inhibitors of ErbB receptor signaling.
Bennasroune A, Fickova M, Gardin A, Dirrig-Grosch S, Aunis D, Crémel G, Hubert P
Molecular biology of the cell 2004 Jul;15(7):3464-74
Molecular biology of the cell 2004 Jul;15(7):3464-74
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G
Cancer research 2004 Jul 15;64(14):4931-41
Cancer research 2004 Jul 15;64(14):4931-41
Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells.
Abuharbeid S, Apel J, Sander M, Fiedler B, Langer M, Zuzarte ML, Czubayko F, Aigner A
Biochemical and biophysical research communications 2004 Aug 20;321(2):403-12
Biochemical and biophysical research communications 2004 Aug 20;321(2):403-12
Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.
Kershaw MH, Jackson JT, Haynes NM, Teng MW, Moeller M, Hayakawa Y, Street SE, Cameron R, Tanner JE, Trapani JA, Smyth MJ, Darcy PK
Journal of immunology (Baltimore, Md. : 1950) 2004 Aug 1;173(3):2143-50
Journal of immunology (Baltimore, Md. : 1950) 2004 Aug 1;173(3):2143-50
Effects of cytochalasin D on the actin cytoskeleton: association of neoformed actin aggregates with proteins involved in signaling and endocytosis.
Mortensen K, Larsson LI
Cellular and molecular life sciences : CMLS 2003 May;60(5):1007-12
Cellular and molecular life sciences : CMLS 2003 May;60(5):1007-12
Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells.
Ramsauer VP, Carraway CA, Salas PJ, Carraway KL
The Journal of biological chemistry 2003 Aug 8;278(32):30142-7
The Journal of biological chemistry 2003 Aug 8;278(32):30142-7
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT
Journal of immunology (Baltimore, Md. : 1950) 2003 Apr 15;170(8):4242-53
Journal of immunology (Baltimore, Md. : 1950) 2003 Apr 15;170(8):4242-53
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT
Journal of immunology (Baltimore, Md. : 1950) 2003 Apr 15;170(8):4242-53
Journal of immunology (Baltimore, Md. : 1950) 2003 Apr 15;170(8):4242-53
Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway.
Stoica GE, Franke TF, Wellstein A, Morgan E, Czubayko F, List HJ, Reiter R, Martin MB, Stoica A
Oncogene 2003 Apr 10;22(14):2073-87
Oncogene 2003 Apr 10;22(14):2073-87
Basolateral targeting of ERBB2 is dependent on a novel bipartite juxtamembrane sorting signal but independent of the C-terminal ERBIN-binding domain.
Dillon C, Creer A, Kerr K, Kümin A, Dickson C
Molecular and cellular biology 2002 Sep;22(18):6553-63
Molecular and cellular biology 2002 Sep;22(18):6553-63
Basolateral targeting of ERBB2 is dependent on a novel bipartite juxtamembrane sorting signal but independent of the C-terminal ERBIN-binding domain.
Dillon C, Creer A, Kerr K, Kümin A, Dickson C
Molecular and cellular biology 2002 Sep;22(18):6553-63
Molecular and cellular biology 2002 Sep;22(18):6553-63
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK
Blood 2002 Nov 1;100(9):3155-63
Blood 2002 Nov 1;100(9):3155-63
Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.
MacKeigan JP, Taxman DJ, Hunter D, Earp HS 3rd, Graves LM, Ting JP
Clinical cancer research : an official journal of the American Association for Cancer Research 2002 Jul;8(7):2091-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2002 Jul;8(7):2091-9
Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain.
Kashentseva EA, Seki T, Curiel DT, Dmitriev IP
Cancer research 2002 Jan 15;62(2):609-16
Cancer research 2002 Jan 15;62(2):609-16
Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA.
Piechocki MP, Pilon SA, Wei WZ
Journal of immunological methods 2002 Jan 1;259(1-2):33-42
Journal of immunological methods 2002 Jan 1;259(1-2):33-42
ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation.
Hsieh SS, Malerczyk C, Aigner A, Czubayko F
International journal of cancer 2000 Jun 1;86(5):644-51
International journal of cancer 2000 Jun 1;86(5):644-51
Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.
Kunisue H, Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, Doihara H, Shimizu N, Sonoo H
British journal of cancer 2000 Jan;82(1):46-51
British journal of cancer 2000 Jan;82(1):46-51
Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol.
Aigner A, Hsieh SS, Malerczyk C, Czubayko F
Toxicology 2000 Apr 3;144(1-3):221-8
Toxicology 2000 Apr 3;144(1-3):221-8
Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol.
Aigner A, Hsieh SS, Malerczyk C, Czubayko F
Toxicology 2000 Apr 3;144(1-3):221-8
Toxicology 2000 Apr 3;144(1-3):221-8
Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.
Tang CK, Concepcion XZ, Milan M, Gong X, Montgomery E, Lippman ME
Cancer research 1999 Oct 15;59(20):5315-22
Cancer research 1999 Oct 15;59(20):5315-22
ErbB-4 ribozymes abolish neuregulin-induced mitogenesis.
Tang CK, Goldstein DJ, Payne J, Czubayko F, Alimandi M, Wang LM, Pierce JH, Lippman ME
Cancer research 1998 Aug 1;58(15):3415-22
Cancer research 1998 Aug 1;58(15):3415-22
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of HER-2/ErbB2 was done on 70% confluent log phase T47D cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with HER-2/ErbB2 (9G6.10) Mouse Monoclonal Antibody (Product # MA5-12759) at 2 µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300).Panel d is a merged image showing cytoplasmic and membranous localization. Panel e is a no primary antibody control. The images were captured at 60X magnification.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of ErbB2 using a monoclonal antibody (Product # MA5-12759).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of ErbB2 using a monoclonal antibody (Product # MA5-12759).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 7 Sub-cellular localization of ERbeta1-5. U2OS cells were plated on cover slips and transiently transfected with Flag-tagged expression vectors for ERbeta1-5 for 24 h. Cells were subsequently fixed, permeabilized, and incubated with either the monoclonal Flag (1:50), MC10 (1:50), or PPG5/10 (1:50) antibodies. Localization of ERbeta1-5 was determined using a FITC-labeled anti-mouse secondary antibody and confocal microscopy. A: The PPG5/10 antibody was only able to detect ERbeta1 expression while the MC10 antibody was able to detect all forms of ERbeta. ERbeta1 and ERbeta2 were completely localized within the cell nucleus while appreciable levels of cytoplasmic localization were also observed for ERbeta3-5 using both the Flag and MC10 antibodies. B: A significant number of cells transfected with ERbeta4 and ERbeta5 expression vectors also exhibited a differential sub-cellular localization pattern characterized by strong peri-nuclear and punctate cytoplasmic staining in the absence of nuclear staining with both the Flag and MC10 antibodies.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 4 Specificity and comparison of the MC10 monoclonal antibody for ERbeta protein to that of other commercial antibodies as determined by immunofluorescence. U2OS cells expressing either Flag-tagged ERbeta or ERalpha under the control of a doxycycline inducible promoter were pelleted, paraffin embedded, sectioned, and processed for immunofluorescence. Sections of un-induced cells, ERbeta expressing cells and ERalpha expressing cells were stained with a monoclonal Flag antibody (1:100) (A), an ERalpha antibody (Dako ID5, 1: 50) (B), or the following ERbeta antibodies: MC10 (1:300) (C), Chemicon (AB1410, 1:400) (D), Santa Cruz (sc-6820, 1:100) (E), Calbiochem (GR40, 1:100) (F), and PPG5/10 (1:100) (G).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 7 Sub-cellular localization of ERbeta1-5. U2OS cells were plated on cover slips and transiently transfected with Flag-tagged expression vectors for ERbeta1-5 for 24 h. Cells were subsequently fixed, permeabilized, and incubated with either the monoclonal Flag (1:50), MC10 (1:50), or PPG5/10 (1:50) antibodies. Localization of ERbeta1-5 was determined using a FITC-labeled anti-mouse secondary antibody and confocal microscopy. A: The PPG5/10 antibody was only able to detect ERbeta1 expression while the MC10 antibody was able to detect all forms of ERbeta. ERbeta1 and ERbeta2 were completely localized within the cell nucleus while appreciable levels of cytoplasmic localization were also observed for ERbeta3-5 using both the Flag and MC10 antibodies. B: A significant number of cells transfected with ERbeta4 and ERbeta5 expression vectors also exhibited a differential sub-cellular localization pattern characterized by strong peri-nuclear and punctate cytoplasmic staining in the absence of nuclear staining with both the Flag and MC10 antibodies.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 1 Relocalization of ErbB2 to the apical surface of polarized Caco-2 cells by over-expression. A: Detection of endogenous ErbB2 on untransfected permeabilized Caco-2 cells. The cells were grown on filters for 10 days and then fixed and challenged with anti-ErbB2 ECD antibody (red). B: Apical localization of transfected (over-expressed) ErbB2. The cells were grown on filters and transfected with ErbB2 4 days after seeding the culture. These confluent non-permeabilized monolayers were fixed and processed with anti-ErbB2 ECD (red channel) from the apical side of the filter. A,B: Single confocal sections in the x - y plane (top panels), and 3D reconstructions of the confocal stack in the x - z plane (perpendicular to the monolayer, apical side up, bottom panels). C: Localization of ErbB2 in polarized mock-transfected Caco-2 cells (empty vector tagged with GFP). The confluent monolayers were transfected with vector expressing GFP as described in (A and B). The fixed, non-permeabilized monolayer was processed for immunofluorescence with anti-ErbB2 ECD antibody (red) only from the apical side of the filter. Scale bars, A-C, 10 um. D: Detection of apical ErbB2 by extracellular biotinylation in ErbB2- (+) and mock-transfected cells (-). Caco-2 cells were grown on filters, transfected as described above and subjected to biotinylation from the apical or basolateral sides of the filter. Triton X-100 extracts were pulled-down with streptavidin-agarose and the SDS eluates separated by PAGE
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 2 Apical localization of ErbB2-activated tyrosine 1139 (pY1139) and phosphorylation of p38 in Caco-2 cells. A: Localization by vectorial biotinylation: Caco-2 cells were transfected with ErbB2 (+) or mock-transfected (-), biotinylated from the apical or basolateral side, and lysed. Biotinylated proteins were pulled-down with streptavidin-coupled beads. Total SDS extracts of SKOV3 cells were used as positive control for the antibody (+c). ErbB2 pY1139 and pY1248 were detected in the precipitates by SDS-PAGE and immunoblot with phospho site specific monoclonal antibodies. Total ErbB2 protein was localized in the same membranes by reprobing. B: Immunofluorescence localization of ErbB2 and its phosphorylated form, pY1139 ErbB2 by confocal microscopy in a confluent polarized Caco-2 cells. The cells were grown on filters, transfected with ErbB2 cDNA, permeabilized, and processed for immunofluorescence with anti-ErbB2 (green) and anti-ErbB2 pY1139 (red) antibodies. Confocal sections are shown in the xy plane and 3D reconstructions of the xz plane are shown apical side up (* non-transfected cell). C: Inhibition of apically localized pY1139 ErbB2 by apical Herceptin. Caco-2 cells were exposed to10 µg/mL Herceptin from the apical side for 24 h, biotinylated from the apical side, and lysed. Biotinylated proteins were pulled-down as described above, and ErbB2 pY1139 was detected by immunoblot. The control for locating the ErbB2 pY1139 band (+c) was performed as described above. Imm